WO2023023647A3 - Compositions et méthodes pour polythérapie antivirale bimodale - Google Patents

Compositions et méthodes pour polythérapie antivirale bimodale Download PDF

Info

Publication number
WO2023023647A3
WO2023023647A3 PCT/US2022/075216 US2022075216W WO2023023647A3 WO 2023023647 A3 WO2023023647 A3 WO 2023023647A3 US 2022075216 W US2022075216 W US 2022075216W WO 2023023647 A3 WO2023023647 A3 WO 2023023647A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
combination therapy
viral
viral combination
Prior art date
Application number
PCT/US2022/075216
Other languages
English (en)
Other versions
WO2023023647A2 (fr
Inventor
Michael Centola
Philip Alex
Original Assignee
Haus Bioceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haus Bioceuticals, Inc. filed Critical Haus Bioceuticals, Inc.
Publication of WO2023023647A2 publication Critical patent/WO2023023647A2/fr
Publication of WO2023023647A3 publication Critical patent/WO2023023647A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/19—Acanthaceae (Acanthus family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/738—Rosa (rose)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Des compositions pharmaceutiques, des kits et des méthodes sont divulgués qui sont destinés à être utilisés pour traiter ou réduire l'apparition d'une infection virale chez un patient. Les compositions, les kits et les méthodes utilisent au moins un agent de réponse anti-pathogène de l'hôte (anti-PHR), soit seul soit en association avec au moins un agent antiviral.
PCT/US2022/075216 2021-08-19 2022-08-19 Compositions et méthodes pour polythérapie antivirale bimodale WO2023023647A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163234902P 2021-08-19 2021-08-19
US63/234,902 2021-08-19

Publications (2)

Publication Number Publication Date
WO2023023647A2 WO2023023647A2 (fr) 2023-02-23
WO2023023647A3 true WO2023023647A3 (fr) 2023-03-30

Family

ID=85241099

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/075216 WO2023023647A2 (fr) 2021-08-19 2022-08-19 Compositions et méthodes pour polythérapie antivirale bimodale

Country Status (1)

Country Link
WO (1) WO2023023647A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070155695A1 (en) * 2004-01-19 2007-07-05 Corinna Wirth Flavonoid complexes with cyclodextrins
US20090082400A1 (en) * 2007-07-31 2009-03-26 Ving Lee Soluble pyrone analogs methods and compositions
WO2016154051A1 (fr) * 2015-03-20 2016-09-29 University Of Florida Research Foundation, Inc. Polythérapie pour le traitement de maladies infectieuses
US20210244705A1 (en) * 2020-02-07 2021-08-12 Centre For Digestive Diseases Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070155695A1 (en) * 2004-01-19 2007-07-05 Corinna Wirth Flavonoid complexes with cyclodextrins
US20090082400A1 (en) * 2007-07-31 2009-03-26 Ving Lee Soluble pyrone analogs methods and compositions
WO2016154051A1 (fr) * 2015-03-20 2016-09-29 University Of Florida Research Foundation, Inc. Polythérapie pour le traitement de maladies infectieuses
US20210244705A1 (en) * 2020-02-07 2021-08-12 Centre For Digestive Diseases Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection

Also Published As

Publication number Publication date
WO2023023647A2 (fr) 2023-02-23

Similar Documents

Publication Publication Date Title
WO2021188969A3 (fr) Vaccins à coronavirus et procédés d'utilisation
NO20030337L (no) Anvendelse av hydroksyetylrutosider i fremstilling av medikamenter til behandling av vanlig forkjolelse, virus- og/eller bakterieinfeksjon i luftveiene og/eller oyne, rhinitt og hoyfeber
NO20090887L (no) Fremgangsmate for behandling og forebygging av mukositt
WO2003086408A8 (fr) Utilisation d'agonistes du recepteur d'adenosine a2a dans le traitement de maladies inflammatoires
WO2007057763A3 (fr) Oxyde nitrique utilisé comme agent antiviral, vaccin et adjuvant de vaccin
BRPI0306993B8 (pt) polímero de polialquilenoglicol ativado; composição; e uso de um composto na produção de um medicamento para o tratamento de esclerose múltipla ou infecção viral suscetível
ZA202211060B (en) Anti-viral compounds and methods for administration thereof
WO2003093462A3 (fr) Immobilisation et stabilisation de virus
WO2005111112A3 (fr) Polymeres a base de cellulose et d'acrylique et leur utilisation dans le traitement de maladies infectieuses
WO2008024843A3 (fr) Méthode de thérapie combinatoire pour le traitement d'une infection par le virus de l'hépatite c et compositions pharmaceutiques correspondantes
WO2022217153A3 (fr) Analogues de nucléosides et de nucléotides utilisés en tant qu'agents antiviraux
CR20230100A (es) Compuestos fosfolípidos y usos de los mismos
MD20190018A2 (ro) Compoziţie, în particular o compoziţie farmaceutică preventivă şi curativă pe bază de peroxometalat
WO2021173713A8 (fr) Composés hautement actifs contre la covid-19
Yoo Uncertainty about the efficacy of remdesivir on COVID-19
WO2021195470A3 (fr) Identification et utilisation de composés dans le traitement ou la prévention du coronavirus 2 responsable du syndrome respiratoire aigu sévère
WO2023023647A3 (fr) Compositions et méthodes pour polythérapie antivirale bimodale
ZA202211706B (en) Medicine/agent for the treatment of coronavirus, retroviral infections and hepatitis c
WO2020252441A3 (fr) Cellules lymphocytaires activées et leurs méthodes d'utilisation pour traiter le cancer et des états infectieux
WO2022020353A3 (fr) Méthodes et compositions pour le traitement et la prévention d'une infection par un coronavirus
WO2021225847A8 (fr) Masque comportant un ou plusieurs orifices auto-obturants et kits chirurgicaux et systèmes associés à ce dernier
WO2008045017A3 (fr) Inhibiteurs des virus sars et ebola, leur utilisation, et procédés pour les découvrir
WO2021194938A9 (fr) Nanoéponge universelle pour le traitement d'une infection virale respiratoire
WO2004033479A3 (fr) Les retrocyclines, des peptides antiviraux et antimicrobiens
WO2022109317A9 (fr) Anticorps contre la grippe et combinaisons de ces derniers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22859425

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE